Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited?

References

• Aday, J. S., Skiles, Z., Eaton, N., Fredenburg, L., Pleet, M., Mantia, J., Bradley, E. R., Fernandes-Osterhold, G., & Woolley, J. D. (2023). Personal psychedelic use is common among a sample of psychedelic therapists: Implications for research and practice. Psychedelic Medicine, 1(1), 27–37. https://doi.org/10.1089/psymed.2022.0004
   Google Scholar
• Andersen, K. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatrica Scandinavica, 143(2), 101–118. https://doi.org/10.1111/acps.13249
   PubMed Web of Science ®Google Scholar
• Barrett, M. S., & Berman, J. S. (2001). Is psychotherapy more effective when therapists disclose information about themselves? Journal of Consulting and Clinical Psychology, 69(4), 597–603. https://doi.org/10.1037/0022-006X.69.4.597
   PubMed Web of Science ®Google Scholar
• Beauchamp, T. L., & Childress, J. F. (2013). Principles of biomedical ethics (7th ed.). Oxford University Press.
   Google Scholar
• Bender, D., & Hellerstein, D. J. (2022). Assessing the risk–benefit profile of classical psychedelics: A clinical review of second-wave psychedelic research. Psychopharmacology, 239(6), 1907–1932. https://doi.org/10.1007/s00213-021-06049-6
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. https://doi.org/10.1177/0269881114565144
   PubMed Web of Science ®Google Scholar
• Brennan, W., Jackson, M. A., MacLean, K., & Ponterotto, J. G. (2021). A qualitative exploration of relational ethical challenges and practices in psychedelic healing. Journal of Humanistic Psychology, 1–31. https://doi.org/10.1177/00221678211045265
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235(2), 399–408. https://doi.org/10.1007/s00213-017-4771-x
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet. Psychiatry, 3(7), 619–627. https://doi.org/10.1016/S2215-0366(16)30065-7
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344. https://doi.org/10.1124/pr.118.017160
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. The New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016). The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychological Medicine, 46(7), 1379–1390. https://doi.org/10.1017/S0033291715002901
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. (2024). Ongoing clinical trials with psilocybin. https://clinicaltrials.gov./search?intr=psilocybin&aggFilters=status:not%20rec%20act
   Google Scholar
• Culbreth, J. R. (2000). Substance abuse counselors with and without a personal history of chemical dependency. Alcoholism Treatment Quarterly, 18(2), 67–82. https://doi.org/10.1300/J020v18n02_05
   Google Scholar
• Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235(11), 3137–3148. https://doi.org/10.1007/s00213-018-5010-9
   PubMed Web of Science ®Google Scholar
• de Vos, J. A., Netten, C., & Noordenbos, G. (2016). Recovered eating disorder therapists using their experiential knowledge in therapy: A qualitative examination of the therapists’ and the patients’ view. Eating Disorders, 24(3), 207–223. https://doi.org/10.1080/10640266.2015.1090869
   PubMed Web of Science ®Google Scholar
• Devenot, N., Tumilty, E., Buisson, M., McNamee, S., Nickles, D., & Ross, L. K. (2022, March 9). A precautionary approach to touch in psychedelic-assisted therapy—Bill of health. https://blog.petrieflom.law.harvard.edu/2022/03/09/precautionary-approach-touch-in-psychedelic-assisted-therapy/
   Google Scholar
• Dubinski, K. (2020, December 10). Some doctors, therapists get Health Canada permission to use magic mushrooms. CBC News. https://www.cbc.ca/news/canada/london/some-doctors-therapists-get-health-canada-permission-to-use-magic-mushrooms-1.5834485
   Google Scholar
• Ducharme, J. (2023, February 8). Psychedelics may be part of U.S. medicine sooner than you think. Time. https://time.com/6253702/psychedelics-psilocybin-mdma-legalization/
   Google Scholar
• Earleywine, M., Low, F., Altman, B. R., & De Leo, J. (2023). How important is a guide who has taken psilocybin in psilocybin-assisted therapy for depression? Journal of Psychoactive Drugs, 55(1), 51–61. https://doi.org/10.1080/02791072.2022.2047842
   PubMed Web of Science ®Google Scholar
• Elliott, M., & Ragsdale, J. (2020). Mental health professionals with mental illnesses: A qualitative interview study. The American Journal of Orthopsychiatry, 90(6), 677–686. https://doi.org/10.1037/ort0000499
   PubMed Web of Science ®Google Scholar
• Emmerich, N., & Humphries, B. (2023). Is the requirement for first-person experience of psychedelic drugs a justified component of a psychedelic therapist’s training? Cambridge Quarterly of Healthcare Ethics, 1–10. https://doi.org/10.1017/S0963180123000099
   PubMed Web of Science ®Google Scholar
• Engel, L. B., Thal, S. B., & Bright, S. J. (2022). Psychedelic forum member preferences for carer experience and consumption behavior: Can “trip sitters” help inform psychedelic harm reduction services? Contemporary Drug Problems, 49(4), 356–368. https://doi.org/10.1177/00914509221121420
   Google Scholar
• Forstmann, M., & Sagioglou, C. (2021). How psychedelic researchers’ self-admitted substance use and their association with psychedelic culture affect people’s perceptions of their scientific integrity and the quality of their research. Public Understanding of Science, 30(3), 302–318. https://doi.org/10.1177/0963662520981728
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088–1101. https://doi.org/10.1177/0269881119845793
   PubMed Web of Science ®Google Scholar
• Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease, 202(7), 513–520. https://doi.org/10.1097/NMD.0000000000000113
   PubMed Web of Science ®Google Scholar
• Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., … Malievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. The New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513
   PubMed Web of Science ®Google Scholar
• Grof, S. (2005). The great awakening: Psychology, philosophy, and spirituality in LSD psychotherapy. In R. Walsh & C. Grob (Eds.), Higher wisdom: Eminent elders explore the continuing impact of psychedelics (pp. 55–67). State University of New York Press.
   Google Scholar
• Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023). Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Research, 329, 115531. https://doi.org/10.1016/j.psychres.2023.115531
   PubMed Web of Science ®Google Scholar
• Haridy, R. (2023). Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature, 619(7969), 227–228. https://doi.org/10.1038/d41586-023-02093-8
   PubMed Web of Science ®Google Scholar
• Hartogsohn, I. (2020). American trip: Set, setting, and the psychedelic experience in the twentieth century. The MIT Press.
   Google Scholar
• Hecksher, D. (2007). Former substance users working as counselors. A dual relationship. Substance Use & Misuse, 42(8), 1253–1268. https://doi.org/10.1080/10826080701446711
   PubMed Web of Science ®Google Scholar
• Hendricks, P. S., & Nichols, C. D. (2023). The elephant in the room: Personal use of psychedelics among psychedelic researchers. Psychedelic Medicine, 1(3), 122–123. https://doi.org/10.1089/psymed.2023.29002.psh
   Google Scholar
• Hoffer, A., & Osmond, H. (1967). The hallucinogens. Academic Press.
   Google Scholar
• Hofmann, A. (2005). LSD, my problem child: Reflections on sacred drugs, mysticism, and science. Multidisciplinary Association for Psychedelic Studies.
   Google Scholar
• Holze, F., Gasser, P., Müller, F., Dolder, P. C., & Liechti, M. E. (2023). Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled phase II study. Biological Psychiatry, 93(3), 215–223. https://doi.org/10.1016/j.biopsych.2022.08.025
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55–60. https://doi.org/10.3109/00952990.2016.1170135
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., Garcia-Romeu, A., Johnson, P. S., & Griffiths, R. R. (2017). An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology, 31(7), 841–850. https://doi.org/10.1177/0269881116684335
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., & Griffiths, R. R. (2017). Potential therapeutic effects of psilocybin. Neurotherapeutics, 14(3), 734–740. https://doi.org/10.1007/s13311-017-0542-y
   PubMed Web of Science ®Google Scholar
• Kious, B., Schwartz, Z., & Lewis, B. (2023). Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. Journal of Psychopharmacology, 37(1), 45–48. https://doi.org/10.1177/02698811221133461
   PubMed Web of Science ®Google Scholar
• Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023). Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Journal of Affective Disorders, 348, 409. https://doi.org/10.1016/j.jad.2022.09.168
   Web of Science ®Google Scholar
• Krebs, T. S., & Johansen, P.-Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994–1002. https://doi.org/10.1177/0269881112439253
   PubMed Web of Science ®Google Scholar
• Kumari, N. (2011). Personal therapy as a mandatory requirement for counselling psychologists in training: A qualitative study of the impact of therapy on trainees’ personal and professional development. Counselling Psychology Quarterly, 24(3), 211–232. https://doi.org/10.1080/09515070903335000
   Google Scholar
• Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PloS One, 19(3), e0300501. https://doi.org/10.1371/journal.pone.0300501
   PubMed Web of Science ®Google Scholar
• Levitt, H., Minami, T., Greenspan, S., Puckett, J., Henretty, J., Reich, C., & Berman, J. (2015). How therapist self-disclosure relates to alliance and outcomes: A naturalistic study. Counselling Psychology Quarterly, 29, 1–22. https://doi.org/10.1080/09515070.2015.1090396
   Google Scholar
• Maia, L. O., Beaussant, Y., & Garcia, A. C. M. (2022). The therapeutic potential of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness: A systematic review. Journal of Pain and Symptom Management, 63(6), e725–e738. https://doi.org/10.1016/j.jpainsymman.2022.01.024
   PubMed Web of Science ®Google Scholar
• Malikiosi-Loizos, M. (2013). Personal therapy for future therapists: Reflections on a still debated issue. The European Journal of Counselling Psychology, 2(1), 33–50. https://doi.org/10.5964/ejcop.v2i1.4
   Google Scholar
• Metzner, R. (2015). Allies for awakening: Guidelines for productive and safe experiences with entheogens. Regent Press.
   Google Scholar
• Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
   PubMed Web of Science ®Google Scholar
• Mitchell, J. M., Ot’alora G, M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, M., Kleiman, S., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., de Boer, A., Doblin, R., & Yazar-Klosinski, B. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10)Article, 10. https://doi.org/10.1038/s41591-023-02565-4
   PubMed Web of Science ®Google Scholar
• Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2018). 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet. Psychiatry, 5(6), 486–497. https://doi.org/10.1016/S2215-0366(18)30135-4
   PubMed Web of Science ®Google Scholar
• Moe, F. D., & Thimm, J. (2021). Personal therapy and the personal therapist. Nordic Psychology, 73(1), 3–28. https://doi.org/10.1080/19012276.2020.1762713
   Web of Science ®Google Scholar
• Nielson, E. M. (2021). Psychedelics as a training experience for psychedelic therapists: Drawing on history to inform current practice. Journal of Humanistic Psychology, 1–17. https://doi.org/10.1177/00221678211021204
   Google Scholar
• Nielson, E. M., & Guss, J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies, 2(2), 64–73. https://doi.org/10.1556/2054.2018.009
   Google Scholar
• Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016). Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Frontiers in Human Neuroscience, 10, 269. https://doi.org/10.3389/fnhum.2016.00269
   PubMed Web of Science ®Google Scholar
• Orlinsky, D. E., Norcross, J. C., Rønnestad, M. H., & Wiseman, H. (2005). Outcomes and impacts of the psychotherapist’s own psychotherapy. In J. D. Geller, J. C. Norcross, & D. E. Orlinsky (Eds.), The psychotherapist’s own psychotherapy: Patient and clinician perspectives (pp. 214–235). Oxford University Press.
   Google Scholar
• Ot’alora G, M., Grigsby, J., Poulter, B., Van Derveer, J. W., Giron, S. G., Jerome, L., Feduccia, A. A., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2018). 3, 4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. Journal of Psychopharmacology, 32(12), 1295–1307. https://doi.org/10.1177/0269881118806297
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., Dos Santos, R. G., Tófoli, L. F., de Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvão-Coelho, N. L., Lobão-Soares, B., … Araújo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine, 49(4), 655–663. https://doi.org/10.1017/S0033291718001356
   PubMed Web of Science ®Google Scholar
• Phelps, J. (2017). Developing guidelines and competencies for the training of psychedelic therapists. Journal of Humanistic Psychology, 57(5), 450–487. https://doi.org/10.1177/0022167817711304
   Web of Science ®Google Scholar
• Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530
   PubMed Web of Science ®Google Scholar
• Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. (2020). Psychedelics and psychedelic-assisted psychotherapy. The American Journal of Psychiatry, 177(5), 391–410. https://doi.org/10.1176/appi.ajp.2019.19010035
   PubMed Web of Science ®Google Scholar
• Romeo, B., Karila, L., Martelli, C., & Benyamina, A. (2020). Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. Journal of Psychopharmacology, 34(10), 1079–1085. https://doi.org/10.1177/0269881120919957
   PubMed Web of Science ®Google Scholar
• Roscoe, J., & Lozy, O. (2022). Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. Drug Science, Policy and Law, 8, 20503245221085222. https://doi.org/10.1177/20503245221085222
   Google Scholar
• Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512
   PubMed Web of Science ®Google Scholar
• Rotz, R., von Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809
   PubMedGoogle Scholar
• Sanches, R. F., de Lima Osório, F., Dos Santos, R. G., Macedo, L. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. (2016). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. Journal of Clinical Psychopharmacology, 36(1), 77–81. https://doi.org/10.1097/JCP.0000000000000436
   PubMed Web of Science ®Google Scholar
• Sherwood, J. N., Stolaroff, M. J., & Harman, W. W. (1962). The psychedelic experience–A new concept in psychotherapy. Journal of Neuropsychiatry, 4, 69–80.
   PubMed Web of Science ®Google Scholar
• Simonsson, O., Carlbring, P., Carhart-Harris, R., Davis, A. K., Nutt, D. J., Griffiths, R. R., Erritzoe, D., & Goldberg, S. B. (2023). Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis. Psychiatry Research, 327, 115349. https://doi.org/10.1016/j.psychres.2023.115349
   PubMed Web of Science ®Google Scholar
• Smith, W. R., & Sisti, D. (2021). Ethics and ego dissolution: The case of psilocybin. Journal of Medical Ethics, 47(12), 807–814. https://doi.org/10.1136/medethics-2020-106070
   Web of Science ®Google Scholar
• Tai, S. J., Nielson, E. M., Lennard-Jones, M., Johanna Ajantaival, R.-L., Winzer, R., Richards, W. A., Reinholdt, F., Richards, B. D., Gasser, P., & Malievskaia, E. (2021). Development and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research. Frontiers in Psychiatry, 12, 586682. https://doi.org/10.3389/fpsyt.2021.586682
   PubMed Web of Science ®Google Scholar
• Timmermann, C., Roseman, L., Williams, L., Erritzoe, D., Martial, C., Cassol, H., Laureys, S., Nutt, D., & Carhart-Harris, R. (2018). DMT models the near-death experience. Frontiers in Psychology, 9, 1424. https://doi.org/10.3389/fpsyg.2018.01424
   PubMed Web of Science ®Google Scholar
• Villiger, D. (2024). Giving Consent to the Ineffable. Neuroethics, 17(1), 11. https://doi.org/10.1007/s12152-024-09545-6
   PubMed Web of Science ®Google Scholar
• Wachter, T., Lüthi, T., & Imhasly, P. (Directors). (2021). Skalpell und Wahn. NZZaS. https://www.nzz.ch/podcast/skalpell-und-wahn-alle-folgen-am-stueck-exklusiv-fuer-abonnenten-ld.1786668
   Google Scholar
• Wackermann, J., Wittmann, M., Hasler, F., & Vollenweider, F. X. (2008). Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neuroscience Letters, 435(1), 51–55. https://doi.org/10.1016/j.neulet.2008.02.006
   PubMed Web of Science ®Google Scholar
• Warren, C. S., Schafer, K. J., Crowley, M. E. J., & Olivardia, R. (2013). Treatment providers with a personal history of eating pathology: A qualitative examination of common experiences. Eating Disorders, 21(4), 295–309. https://doi.org/10.1080/10640266.2013.797318
   PubMed Web of Science ®Google Scholar
• Wheeler, S. W., & Dyer, N. L. (2020). A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future. Psychology of Consciousness: Theory, Research, and Practice, 7, 279–315. https://doi.org/10.1037/cns0000237
   Google Scholar
• Yaden, D. B., Earp, B. D., & Griffiths, R. R. (2022). Ethical issues regarding nonsubjective psychedelics as standard of care. Cambridge Quarterly of Healthcare Ethics, 31(4), 464–471. https://doi.org/10.1017/S096318012200007X
   PubMed Web of Science ®Google Scholar
• Yaden, D. B., & Griffiths, R. R. (2020). The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science, 4(2), 568–572. https://doi.org/10.1021/acsptsci.0c00194
   PubMedGoogle Scholar